View Older Stories
-
Acadia Pharmaceuticals (ACAD) PT Raised to $35 at Citizens: Potential for Robust Growth
-
Acadia Pharma (ACAD) Tops Q4 EPS by 146c ; Offers Guidance
-
Wolfe Research Starts Acadia Pharmaceuticals (ACAD) at Outperform
-
Acadia Pharma (ACAD) call put ratio 37 calls to 1 put with a focus on March calls as share price up 1.4%
-
Mizuho Upgrades Acadia Pharmaceuticals (ACAD) to Outperform
-
Acadia Pharmaceuticals (ACAD) PT Raised to $23 at Oppenheimer
-
Acadia Pharmaceuticals (ACAD) PT Lowered to $31 at RBC Capital
-
H.C. Wainwright Reiterates Buy Rating on Acadia Pharmaceuticals (ACAD)
-
Canaccord Genuity Reiterates Buy Rating on Acadia Pharmaceuticals (ACAD)
-
Acadia Pharmaceuticals (ACAD) Reiterated at Market Outperform by Citizens
-
ACADIA receives negative trend vote from EU regulators on Rett drug
-
Canaccord Genuity Reiterates Buy Rating on Acadia Pharmaceuticals (ACAD)
-
Acadia Pharma anticipates 2025 net sales to exceed $1 billion
-
ACADIA projects $1.7 billion in 2028 sales, launches new DAYBUE formulation
-
Needham Names MindMed (MNMD) New Top Pick for 2026, Adds to Conviction List
-
Acadia Pharmaceuticals (ACAD) PT Raised to $37 at H.C. Wainwright
-
Acadia Pharmaceuticals (ACAD) PT Raised to $25 at Stifel
-
Acadia Pharmaceuticals (ACAD) PT Lowered to $35 at UBS, Stock Still a 'Top Idea'
-
Acadia Pharmaceuticals (ACAD) PT Raised to $29 at Mizuho
-
Where can biotech stocks go from here? RBC answers
-
Acadia Pharmaceuticals (ACAD) PT Lowered to $22 at RBC Capital
-
Acadia Pharmaceuticals (ACAD) PT Lowered to $32 at RBC Capital
-
Acadia Pharma (ACAD) Tops Q3 EPS by 28c, provides guidance
-
ACADIA Pharmaceuticals board member Daniel Soland resigns
-
Citi Starts Acadia Pharmaceuticals (ACAD) at Buy
-
Biotech stocks: Q3 earnings preview
-
Mizuho Reiterates Neutral Rating on Acadia Pharmaceuticals (ACAD)
-
Acadia Pharmaceuticals to present clinical data at movement disorders congress
-
BMO Capital Cuts Acadia Pharmaceuticals (ACAD) Stock PT Following ACP-101 Miss
-
Acadia Pharmaceuticals (ACAD) PT Lowered to $21 at Oppenheimer
-
Acadia Pharmaceuticals (ACAD) PT Lowered to $35 at TD Cowen
-
Leerink on Acadia (ACAD): 'Despite the news, we still like the stock'
-
BofA Son Acadia (ACAD): 'our focus continues to be on the reacceleration of the Daybue launch in Rett syndrome'
-
Baird: 'Acadia shares should come out relatively unscathed after the dust settles'
-
ACAD failure eliminates a competitive threat to Soleno Therapeutics (SLNO) - Oppenheimer
-
BMO Capital: 'expect ACAD shares to decline'
-
Wells Fargo on Soleno Therapeutics Inc. (SLNO): 'We Think Shares Should Trade Up at Least +20% on ACAD Failure'
-
Stifel on Soleno Therapeutics Inc. (SLNO): 'we remain bullish and believe Vykat is well-positioned for significant/sustained growth'
-
Stifel Reiterates Hold Rating on Acadia Pharmaceuticals (ACAD)
-
Acadia Pharma (ACAD) to Resume Trading at 7:30 a.m.
-
Acadia Pharma (ACAD) Halted, News Pending
-
UBS Reiterates Buy Rating on Acadia Pharmaceuticals (ACAD)
-
Citizens JMP Reiterates Market Outperform Rating on Acadia Pharmaceuticals (ACAD)
-
ACADIA publishes real-world data on DAYBUE for Rett syndrome treatment
-
Acadia Pharmaceuticals (ACAD) PT Raised to $39 at TD Cowen
-
RBC Capital on Biotech Shares: 'Company-Specific Volatility For Quality Names May Be Overdone'
-
Acadia Pharmaceuticals (ACAD) PT Lowered to $22 at Mizuho
-
Acadia Pharmaceuticals (ACAD) PT Raised to $24 at Stifel
-
Acadia Pharmaceuticals (ACAD) PT Raised to $24 at Mizuho
-
Acadia Pharmaceuticals (ACAD) PT Raised to $38 at Citizens JMP

